



Prevents sudden and excessive urination while maintaining diuretic efficacy.

Try SOAANZ®

If patients continue to experience:

- Refractory edema
- Signs of worsening HF
- Worsening bladder problems

Features of SOAANZ®

- Reduces peak urination
- Maintains natriuresis up to 8h
- Does not cause excessive urination

¹Shah S, et. al. (2017). Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action. JAHA. 6(10):e006135.

²See SOANNZ prescriber information (6.1).

³Palmer MH et. al. (2009). Urinary incontinence and overactive bladder in patients with heart failure. J. Urol. 82(1): 196-202

⁴SOANNZ is not studied in patients with bladder problems (or OAB).

⁵Ekundayo OJ et al. (2009). Association of diuretic use and overactive bladder syndrome in older adults: a propensity score analysis. Arch Gerontol Geriatr. 49(1):64-8.



slow release torsemide formulation

- Maintains natriuretic efficacy¹
- Lowers drug conc. by 70%¹
- Reduces peak urination by 30%¹

SOAANZ releases drug slowly and it is not equivalent to generic torsemide

Save up to 75% with GoodRx coupon

SOAANZ is covered under most health plans and is available at:

- Chain Pharmacies
- Independent Pharmacies
- Mail-order Pharmacies

Request free samples from sarfez.com

Sarfez Pharmaceuticals, Inc
Vienna, VA, 22182
info@sarfez.com
www.sarfez.com
1-866-4-SOAANZ



slow release torsemide formulation

- No acute and excessive urination²
- Maintains diuretic efficacy
- Induces natriuresis for up to 8h¹

SOAANZ




May help patients whose bladder problems get worse with the use of a generic loop diuretic.³



SOAANZ is not equivalent to generic torsemide

CLINICAL STUDIES

SOAANZ releases drug slowly and does not cause excessive or abrupt urination



HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use SOAANZ® safely and effectively. See full prescribing information for SOAANZ.

SOAANZ (torsemide) tablets, for oral use

Initial U.S. Approval: 1993

INDICATIONS AND USAGE

SOAANZ is a loop diuretic indicated in adults for the treatment of edema associated with heart failure or renal disease. (1)

DOSAGE AND ADMINISTRATION

The recommended initial dose is 20 mg orally once daily. Titrate dose by approximately doubling until desired diuretic response is obtained. Doses above 200 mg have not been studied.(2)

DOSAGE FORMS AND STRENGTHS

Tablets: 20 mg, 40 mg and 60 mg (3)

CONTRAINDICATIONS

Hypersensitivity to SOAANZ, anuria, and hepatic coma. (4)

WARNINGS AND PRECAUTIONS

- Hypotension and worsening renal function: monitor volume status and renal function periodically (5.1)
- Electrolyte and metabolic abnormalities: monitor serum electrolytes and blood glucose periodically. (5.2)
- Ototoxicity (5.3, 7.6)

ADVERSE REACTIONS

Discontinuation of therapy due to adverse reactions occurred in 6% of patients treated with SOAANZ (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Sarfez Pharmaceuticals Inc. at 1-703-627-1934 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Non-steroidal anti-inflammatory drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects; risk of renal impairment. (7.1)
- CYP2C9: Concomitant use with CYP2C9 inhibitors can decrease torsemide clearance. Torsemide may affect the efficacy and safety of sensitive CYP2C9 substrates or of substrates with a narrow therapeutic range, such as warfarin or phenytoin. (7.2)

- Cholestyramine: Decreased exposure of SOAANZ. (7.3)
- Organic anion drugs: may decrease diuretic activity of SOAANZ. (7.4)
- Lithium: Risk of lithium toxicity. (7.5)
- Renin-angiotensin inhibitors: Increased risk of hypotension and renal impairment. (7.7)
- Radiocontrast agents: Increased risk of renal toxicity. (7.8)
- Corticosteroids and ACTH: Increased risk of hypokalemia. (7.9)

See 17 for PATIENT COUNSELING INFORMATION

FULL PRESCRIBING INFORMATION is available at Sarfezpharma.com

HOW SUPPLIED/STORAGE AND HANDLING

SOAANZ tablets are available as round, film-coated, debossed on one side in the following configurations:

Strength	Color	Bottle of 30 Tablets	Bottle of 90 Tablets
20 mg	Yellow	NDC 73502-786-07	NDC 73502-786-08
40 mg	Orange	NDC 73502-586-10	NDC 73502-586-11
60 mg	Pink	NDC 73502-687-13	NDC 73502-687-14

PATIENT COUNSELING INFORMATION

Symptomatic Hypotension: Advise patients receiving SOAANZ that lightheadedness can occur, especially during the first days of therapy, and that it should be reported to the prescribing physician. Patients should be told that if syncope occurs, SOAANZ should be discontinued until the physician has been consulted.

All patients should be cautioned that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope [see Warnings and Precautions (5.1)].

Non-Steroidal Anti-inflammatory Drugs (NSAID): Advise patients to discuss with their physician before taking NSAID medications concomitantly [see Drug Interactions (7.1)].

SOAANZ®

torsemide tablets

treatment of edema associated with
heart failure or kidney disease



✓ Slow drug release ✓ No excessive urination

Get SOAANZ® at more than
75% discount

[Click here](#) for a discount coupon

Specially formulated for patients whose bladder symptoms
get worse with the use of a loop diuretic; or have

- persistent edema
- symptoms of worsening heart failure
- problem of excessive urination
- developed hypokalemia

Benefits of SOAANZ®

Duration of action 6-8 hours

May help with incidences of hypokalemia

May reduce excessive urination

Highlights Of Prescribing Information

These highlights do not include all the information needed to use SOAANZ® safely and effectively. See full prescribing information for SOAANZ.

SOAANZ (torsemide) tablets, for oral use

INDICATIONS AND USAGE

SOAANZ is a loop diuretic indicated in adults for the treatment of edema associated with heart failure or renal disease. (1)

DOSAGE AND ADMINISTRATION

The recommended initial dose is 20 mg orally once daily. Titrate dose by approximately doubling until desired diuretic response is obtained. Doses above 200 mg have not been studied.(2)

DOSAGE FORMS AND STRENGTHS

Tablets: 20 mg, 40 mg and 60 mg (3)

CONTRAINDICATIONS

Hypersensitivity to SOAANZ, anuria, and hepatic coma. (4)

To report SUSPECTED ADVERSE REACTIONS, contact Sarfez Pharmaceuticals Inc. at 1-877-8-SARFEZ or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Non-steroidal anti-inflammatory drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects; risk of renal impairment. (7.1)
- CYP2C9: Concomitant use with CYP2C9 inhibitors can decrease torsemide clearance. Torsemide may affect the efficacy and safety of sensitive CYP2C9 substrates or of substrates with a narrow therapeutic range, such as warfarin or

WARNINGS AND PRECAUTIONS

- Hypotension and worsening renal function: monitor volume status and renal function periodically (5.1)
- Electrolyte and metabolic abnormalities: monitor serum electrolytes and blood glucose periodically. (5.2)
- Ototoxicity (5.3, 7.6)

ADVERSE REACTIONS

Discontinuation of therapy due to adverse reactions occurred in 6% of patients treated with SOAANZ (6.1).

phenytoin. (7.2)

- Cholestyramine: Decreased exposure of SOAANZ. (7.3)
- Organic anion drugs: may decrease diuretic activity of SOAANZ. (7.4)
- Lithium: Risk of lithium toxicity. (7.5)
- Renin-angiotensin inhibitors: Increased risk of hypotension and renal impairment. (7.7)
- Radiocontrast agents: Increased risk of renal toxicity. (7.8)
- Corticosteroids and ACTH: Increased risk of hypokalemia. (7.9)

PATIENT COUNSELING INFORMATION

Symptomatic Hypotension: Advise patients receiving SOAANZ that lightheadedness can occur, especially during the first days of therapy, and that it should be reported to the prescribing physician. Patients should be told that if syncope occurs, SOAANZ should be discontinued until the physician has been consulted.

All patients should be cautioned that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope [see Warnings and Precautions (5.1)].

Non-Steroidal Anti-inflammatory Drugs (NSAID): Advise patients to discuss with their physician before taking NSAID medications concomitantly [see Drug Interactions (7.1)].

SARFEZ and SOAANZ are registered trademarks of Sarfez. Any other trademarks are the property of their respective owners.

Manufactured For:
Sarfez Pharmaceuticals Inc.

Vienna, VA 22182

Address

8000 Towers Crescent Drive
Suite 1302
Vienna, VA 22182

Contact

info@sarfez.com
1-877-872-7339





Slow Drug Release Novel Torsemide Formulation May Help Patients With Bladder Sensitivity

SOAANZ is an FDA approved drug to treat edema associated with heart failure and renal diseases.



Get SOAANZ® at more than
75% discount

[Click here](#) for a discount coupon

SOAANZ May Help Patients Who Experience Worsening Bladder Problems With The Use Of Generic Loop Diuretics.

If you are a heart failure patient experiencing bladder issues from generic loop diuretics, SOAANZ may help.

Key Benefits Of SOAANZ:

SOAANZ does not cause excessive or acute urination but retains diuretic effectiveness.

Have a look at some key benefits of SOAANZ:



Releases Drug Slowly



Causes No Excessive Urination



Maintains Natriuresis For Up to 8 hours.

Highlights Of Prescribing Information

Indications And Usage

SOAANZ is a loop diuretic indicated in adults for the treatment of edema associated with heart failure or renal disease. (1)

To report SUSPECTED ADVERSE REACTIONS, contact Sarfez Pharmaceuticals Inc. at 1-877-8-SARFEZ or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Dosage And Administration

The recommended initial dose is 20 mg orally once daily. Titrate dose by approximately doubling until desired diuretic response is obtained. Doses above 200 mg have not been studied.(2)

Dosage Forms And Strengths

Tablets: 20 mg, 40 mg and 60 mg (3)

Contraindications

Drug Interactions

- Non-steroidal anti-inflammatory drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects; risk of renal impairment. (7.1)
- CYP2C9: Concomitant use with CYP2C9 inhibitors can decrease torsemide clearance. Torsemide may affect the efficacy and safety of sensitive CYP2C9 substrates or of substrates with a narrow therapeutic range, such as warfarin or phenytoin. (7.2)

Hypersensitivity to SOAANZ, anuria, and hepatic coma. (4)

Warnings And Precautions

- Hypotension and worsening renal function: monitor volume status and renal function periodically (5.1)
- Electrolyte and metabolic abnormalities: monitor serum electrolytes and blood glucose periodically. (5.2)
- Ototoxicity (5.3, 7.6)

- Cholestyramine: Decreased exposure of SOAANZ. (7.3)
- Organic anion drugs: may decrease diuretic activity of SOAANZ. (7.4)
- Lithium: Risk of lithium toxicity. (7.5)
- Renin-angiotensin inhibitors: Increased risk of hypotension and renal impairment. (7.7)
- Radiocontrast agents: Increased risk of renal toxicity. (7.8)
- Corticosteroids and ACTH: Increased risk of hypokalemia. (7.9)

[Full PDF](#)

Adverse Reactions

Discontinuation of therapy due to adverse reactions occurred in 6% of patients treated with SOAANZ (6.1).

Address

8000 Towers Crescent Drive
Suite 1302
Vienna, VA 22182

Contact

1-866-476-2269

Email Us

info@sarfez.com

©2023 by Sarfez Pharmaceuticals, Inc.



SOAANZ
torsemide tablets

✓ SLOW DRUG RELEASE

✓ NO EXCESSIVE URINATION

May benefit heart failure patients who feel sudden
need to urinate with use of a loop diuretic*



*Disclaimer: Inferential claim; SOAANZ is not studied in patients with bladder instability

SARFEZ
Pharmaceuticals Inc



MEDAXIOM
AN ACC COMPANY

TRANSFORMING
CARDIOVASCULAR CARE, TOGETHER



**BEAUTIFUL INTERIM
SERVICES**





SOAANZ
torsemide tablets

- ✓ SLOW DRUG RELEASE
- ✓ NO EXCESSIVE URINATION

May benefit heart failure patients who feel sudden
need to urinate with use of a loop diuretic*

*Disclaimer: Inferential claim: SOAANZ is not studied in patients with bladder instability

SARFEZ
Pharmaceuticals Inc.

AMERICAN
COLLEGE OF
CARDIOLOGY®

AMERICAN
COLLEGE OF
CARDIOLOGY

TRANSFORMING CARDIOVASCULAR CARE FOR ALL

AMGEN

TRANSFORMING CARDIOVASCULAR CARE FOR ALL

AMERICAN
COLLEGE OF
CARDIOLOGY®

JAMA Network®

JAMA Network®

JAMA Network™

